儿童急性淋巴细胞白血病免疫表型与生存期的探讨  

Relationship Between Immunophenotype and Event-Free Survival in Children with Acute Lymphoblastic Leukemia

作　　者：李卫[1] 杜玲珍[1] 王耀莉[1] 倪麟[2] 陈松立[2] 

机构地区：[1]上海第二医科大学瑞金医院儿内科,上海200025 [2]上海第二医科大学瑞金医院检验系

出　　处：《上海第二医科大学学报》2001年第4期356-358,共3页Acta Universitatis Medicinalis Secondae Shanghai

摘　　要：目的探讨儿童急性淋巴细胞白血病 (ALL)免疫表型与无病生存期 (EFS)的关系。　方法对 48例初发未治疗的儿童ALL ,用免疫酶标法测其骨髓肿瘤细胞的免疫表型。治疗采用 1993年北海会议制定的《小儿白血病诊疗建议》。　结果 40例为My-BL ,其首次诱导完全缓解 (CR)率 97.5 % ,化疗 2年内EFS 82 .5 % ,3年内EFS72 .5 %。 4例My+BL ,首次诱导CR率 5 0 % ,化疗 2年内EFS 2 5 %。 3例My-TL首次诱导均CR ,但EFS与My+BL基本类似。Objective To investigate the relationship between immunophenotype and event-free survival (EFS) in children with acute lymphoblastic leukemia (ALL). Methods The malignant cells on slides from the bone marrow of 48 untreated pediatric ALL patients (younger than 15 years) were examined with the immunoenzymatic method using avidin-biotin-immunoalkaline phosphatase to evaluate this immunophenotypes. A panel of monoclonal antibodies included B cell markers CD 10 , CD 19 ,CD 20 and HLA-DR; T cell markers CD 1,CD 2,CD 3,CD 4,CD 5,CD 7 and CD 8, myeloid markers: CD 34 , CD 68 and MPO. These patients were treated according to the“Diagnosis and Treatment Protocol of Children AL” suggested by the National Children AL Conference in 1993. Results Forty of 48 patients were My -BL (myeloid antigen negative B-ALL), 97.9% of them achieved complete remission (CR) after first induction therapy, 82.5% of them were EFS in 2 years and 72.5% in 3 years duration of chemotherapy, respectively. Four patients were My +BL (myeloid antigen positive B-ALL), two (50%) got CR after first induction therapy, and only one (25%) was alive in 2 years. Three patients were My -TL, they all achieved CR after first induction therapy, but their EFS was shorter, no one was alive in 2 years. Conclusion These results suggested at present that immunophenotyps is important in judging the therapeutic effect and EFS of children ALL.

关 键 词：急性淋巴细胞白血病 免疫表型 生存期 儿童 

分 类 号：R733.71[医药卫生—肿瘤]